Document is current
Any future updates will be listed below
-
Authors
Quintanal-Villalonga, Alvaro http://orcid.org/0000-0002-7234-3446
Kawasaki, Kenta
Redin, Esther
Uddin, Fathema
Rakhade, Swanand
Durani, Vidushi
Sabet, Amin
Shafer, Moniquetta
Karthaus, Wouter R.
Zaidi, Samir
Zhan, Yingqian A. http://orcid.org/0000-0002-3548-9227
Manoj, Parvathy
Sridhar, Harsha
Kinyua, Dennis
Zhong, Hong
Mello, Barbara P.
Ciampricotti, Metamia
Bhanot, Umesh K.
Linkov, Irina
Qiu, Juan
Patel, Radhika A.
Morrissey, Colm
Mehta, Sanjoy
Barnes, Jesse
Haffner, Michael C.
Socci, Nicholas D.
Koche, Richard P.
de Stanchina, Elisa
Molina-Pinelo, Sonia
Salehi, Sohrab
Yu, Helena A.
Chan, Joseph M.
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
- License Information
-
More Information
Article History
Received: 19 February 2024
Revised: 20 June 2024
Accepted: 30 June 2024
First Online: 26 July 2024
Competing interests
: A.Q.V. has received honoraria from Astra Zeneca. W.R.K. is an inventor of organoid technology. He is a science advisor to Arsenal, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ and PMV. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics. A.Q.V. and C.M.R. have filed a patent application entitled “Methods for treating or preventing neuroendocrine tumor formation using CDC7 inhibitors” (U.S. Provisional Patent Application No.: 63/416,702).
